Long-term outcomes in patients with advanced and/or metastatic non-small cell lung cancer who completed 2 years of immune checkpoint inhibitors or achieved a durable response after discontinuation without disease progression: Multicenter, real-world data (KCSG LU20-11).
Journal Information
Full Title: Cancer
Abbreviation: Cancer
Country: Unknown
Publisher: Unknown
Language: N/A
Publication Details
Related Papers from Same Journal
Transparency Score
Transparency Indicators
Click on green indicators to view evidence textCore Indicators
"Conflict of Interest Disclosures Dong‐Wan Kim reports research funding from Alpha Biopharma, Amgen, AstraZeneca/Medimmune, Boehringer‐Ingelheim, Daiichi‐Sankyo, Hanmi, Janssen, Merus, Mirati Therapeutics, MSD, Novartis, ONO Pharmaceutical, Pfizer, Roche/Genentech, Takeda, TP Therapeutics, Xcovery, Yuhan, Chong Keun Dang, Bridge BioTherapeutics, and GSK and travel and accommodation support for advisory board meeting attendance from Amgen and Daiichi‐Sankyo. Youngjoo Lee reports participation on boards for Roche Korea and Yuhan Corporation. Hee Kyung Ahn reports payments or honoraria from Yuhan, BMS, MSD, AstraZeneca, Roche, Lilly, Pfizer, and Menarini. Myung‐Ju Ahn reports consulting fees from Alpha Pharmaceuticals and payments or honoraria from MSD, Merck, Lilly, AstraZeneca, Takeda, Yuhan, and Roche. The other authors made no disclosures."
Additional Indicators
Assessment Info
Tool: rtransparent
OST Version: N/A
Last Updated: Aug 05, 2025